<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520946</url>
  </required_header>
  <id_info>
    <org_study_id>RAMTAS</org_study_id>
    <secondary_id>2017-004162-99</secondary_id>
    <nct_id>NCT03520946</nct_id>
  </id_info>
  <brief_title>RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients</brief_title>
  <acronym>RAMTAS</acronym>
  <official_title>A Phase III Study of RAMucirumab in Combination With TAS102 vs. TAS102 Monotherapy in Chemotherapy Refractory Metastatic Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trium Analysis Online GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional, prospective, randomized (1:1), controlled, open label, multicenter phase IIb&#xD;
      study in patients with advanced metastatic colorectal cancer. The scope of the trial is to&#xD;
      evaluate overall survival of either regimen (TAS102 +/- Ramucirumab) and evaluate safety and&#xD;
      tolerability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, prospective, randomized (1:1), controlled, open label, multicenter&#xD;
      phase IIb study in patients with advanced metastatic colorectal cancer. The scope of the&#xD;
      trial is to evaluate overall survival of either regimen and evaluate safety and tolerability.&#xD;
&#xD;
      Patients with advanced metastatic and inoperable, colorectal cancer who have progressed&#xD;
      on/after or did not tolerate: fluoropyrimidines, oxaliplatin, irinotecan, anti-angiogenic&#xD;
      therapies (bevacizumab, aflibercept, regorafenib or ramucirumab) and when indicated anti-EGFR&#xD;
      (epidermal growth factor receptor) antibodies (cetuximab or panitumumab) will be included in&#xD;
      this trial.&#xD;
&#xD;
      Patients will be stratified by the duration of previous anti-angiogenic therapy ≥ or &lt;12&#xD;
      months in total, BRAF V600E mutation status (mutation vs. wildtype), RAS mutation status&#xD;
      (mutation vs. wildtype), and randomized 1:1 to receive either ramucirumab/TAS102 (arm A) or&#xD;
      TAS102 (arm B). Concurrent use of other chemotherapy is not allowed.&#xD;
&#xD;
      Two interim safety analyses will be conducted when 10 and 40 patients are fully documented in&#xD;
      arm A after receiving 2 cycles (one 4-week cycle comprises ramucirumab 8mg/kg administered at&#xD;
      d1 and d15 and TAS102 35mg/m2 p.o. twice daily administered on d1-5 and d8-12). The analysis&#xD;
      will be reviewed by the lead coordinating investigator (Prof. Dr. Kasper) and members of the&#xD;
      steering committee and then by the data safety monitoring board. It is not planned to&#xD;
      discontinue recruitment for the interim safety analyses.&#xD;
&#xD;
      Arm A (ramucirumab/TAS102) Patients randomized to arm A will receive ramucirumab 8 mg/kg iv&#xD;
      over 60 min on d1+15, q4w and TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until&#xD;
      progression or intolerance or completion of 6 cycles.&#xD;
&#xD;
      Arm B (TAS102) Patients randomized to arm B will receive TAS102 35mg/m2 p.o. twice daily&#xD;
      (BID) d1-5 and 8-12, q4w until progression, intolerance or completion of 6 cycles.&#xD;
&#xD;
      In both arms, tumor assessments (CT or MRI) are performed before enrollment/randomization and&#xD;
      then every 8 weeks (every 2nd cycle) during therapy and every 12 weeks during follow-up until&#xD;
      progression/relapse, death or end of follow-up. A change from CT into MRI in the follow-up&#xD;
      period is possible at any time.&#xD;
&#xD;
      During treatment, clinical visits (blood cell counts, detection of toxicity) will be&#xD;
      performed prior to every treatment dose of ramucirumab or every two weeks in arm B or if&#xD;
      ramucirumab was discontinued in arm A. Safety of TAS102 +/- ramucirumab will be monitored&#xD;
      continuously by careful monitoring of all adverse events (AEs) and serious adverse events&#xD;
      (SAEs) reported. Every 4 weeks during therapy Quality of life (QoL) will be assessed using&#xD;
      the European Organization for Research and Treatment of Cancer Quality of Life&#xD;
      Questionnaire-C30 (EORTC-QLQ-C30) and the EuroQol 5 dimensions 5-level version (EQ-5D-5L).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Overall survival according to Kaplan-Meier</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>ORR defined as the proportion of patients with complete or partial remission according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>DCR defined as the proportion of patients with complete or partial remission and stable disease according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>PFS, defined as the time from enrollment/randomization to the first occurrence of progression, as determined by the investigator using CT criteria, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) rate at different time points</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>OS rate at 6 and 12 months, defined as patients who are alive after at 6 and 12 months, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (ORR) subgroup</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Efficacy (ORR) in patients who develop neutropenia grade ≥2 (ANC ≤1500/μl) in cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (PFS) subgroup</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Efficacy (PFS) in patients who develop neutropenia grade ≥2 (ANC ≤1500/μl) in cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (OS) subgroup</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Efficacy (OS) in patients who develop neutropenia grade ≥2 (ANC ≤1500/μl) in cycle 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life I (QoL)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Quality of life (QoL) as measured by EORTC-QLQ-C30 at d1 of each cycle and on EOT (end of treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life II (QoL)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Quality of life (QoL) as measured by EQ-5D-5L at d1 of each cycle and on EOT.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Explorative: Overall response rate (ORR)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>ORR according to gene expression, mutational profiles, plasma biomarkers and radiologic analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative: Overall survival (OS)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>OS according to gene expression, mutational profiles, plasma biomarkers and radiologic analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative: Progression-free survival (PFS)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>PFS according to gene expression, mutational profiles, plasma biomarkers and radiologic analysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">426</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (ramucirumab + TAS102)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to arm A will receive ramucirumab 8 mg/kg iv over 60 min on d1+15, q4w and TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression or intolerance or completion of 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (TAS102 only)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to arm B will receive TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression, intolerance or completion of 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>8 mg/kg iv over 60 min on d1+15, q4w</description>
    <arm_group_label>Arm A (ramucirumab + TAS102)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS 102</intervention_name>
    <description>35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w</description>
    <arm_group_label>Arm A (ramucirumab + TAS102)</arm_group_label>
    <arm_group_label>Arm B (TAS102 only)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Metastatic and inoperable, colorectal cancer who has progressed on/after, or did not&#xD;
             tolerate, refuse or have contraindications to: fluoropyrimidines, oxaliplatin,&#xD;
             irinotecan, anti-angiogenic therapies (bevacizumab, aflibercept, regorafenib or&#xD;
             ramucirumab) and if indicated anti-EGFR antibodies (cetuximab or panitumumab).&#xD;
&#xD;
             Intolerance is defined as a permanent discontinuation of the respective treatment&#xD;
             resulting from toxicity&#xD;
&#xD;
          2. Signed informed consent before start of specific protocol procedure&#xD;
&#xD;
          3. Histologically or cytologically documented diagnosis of adenocarcinoma of the colon or&#xD;
             rectum&#xD;
&#xD;
          4. Presence of at least one measurable site of disease following RECIST 1.1 criteria&#xD;
&#xD;
          5. ECOG (Eastern Cooperative Oncology Group) performance 0-1&#xD;
&#xD;
          6. Known RAS and BRAF V600E mutational status&#xD;
&#xD;
          7. Life expectancy of at least 3 months&#xD;
&#xD;
          8. Adequate hematological, hepatic and renal function parameters:&#xD;
&#xD;
               1. Leukocytes ≥3000/mm³, platelets ≥100,000/mm³, neutrophil count (ANC) ≥1500/μL,&#xD;
                  hemoglobin ≥9 g/dL (5.58 mmol/L)&#xD;
&#xD;
               2. Adequate coagulation function as defined by International Normalized Ratio (INR)&#xD;
                  ≤1.5, and a partial thromboplastin time (PTT) ≤5 seconds above the ULN (upper&#xD;
                  limit of normal) (unless receiving anticoagulation therapy). Patients receiving&#xD;
                  warfarin/phenprocoumon must be switched to low molecular weight heparin and have&#xD;
                  achieved a stable coagulation profile prior to first dose of protocol therapy&#xD;
&#xD;
               3. Serum creatinine ≤1.5 x upper limit of normal or creatinine clearance (measured&#xD;
                  via 24-hour urine collection) ≥40 mL/minute (that is, if serum creatinine is &gt;1.5&#xD;
                  times the ULN, a 24-hour urine collection to calculate creatinine clearance must&#xD;
                  be performed)&#xD;
&#xD;
               4. Urinary protein ≤1+ on dipstick or routine urinalysis (UA; if urine dipstick or&#xD;
                  routine analysis is ≥2+, a 24-hour urine collection for protein must demonstrate&#xD;
                  &lt;1000 mg of protein in 24 hours to allow participation in this protocol)&#xD;
&#xD;
               5. Bilirubin ≤1.5 x upper limit of normal, AST and ALT ≤3.0 x upper limit of normal,&#xD;
                  ≤5xULN if liver metastasis present, alkaline phosphatase ≤6 x upper limit of&#xD;
                  normal&#xD;
&#xD;
          9. Patient able and willing to provide written informed consent and to comply with the&#xD;
             study protocol&#xD;
&#xD;
         10. Female and male patients ≥18. Patients in reproductive age must be willing to use&#xD;
             adequate contraception during the study and for 7 months after the end of ramucirumab&#xD;
             treatment (appropriate contraception is defined as surgical sterilization (e.g.,&#xD;
             bilateral tubal ligation, vasectomy) or hormonal contraception (implantable, patch,&#xD;
             oral). Women who use a hormonal contraception method should use an additional barrier&#xD;
             method like IUD, male or female condom with spermicidal gel, diaphragm, sponge,&#xD;
             cervical cap). Female patients with childbearing potential need to have a negative&#xD;
             pregnancy test within 7 days before study start (There are no data that indicate&#xD;
             special gender distribution. Therefore, patients will be enrolled in the study&#xD;
             gender-independently.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity against ramucirumab or TAS102&#xD;
&#xD;
          2. Other known contraindications against ramucirumab, TAS102, or other anti-angiogenic&#xD;
             therapies&#xD;
&#xD;
          3. Prior therapy with TAS102&#xD;
&#xD;
          4. Drug-related severe adverse events upon pretreatment with antiangiogenic drugs that&#xD;
             would require permanent discontinuation and not allow re-challenge with the same class&#xD;
             of drug (i.e. ramucirumab) such as noncontrollable severe hypertension or&#xD;
             thromboembolic events&#xD;
&#xD;
          5. Any antineoplastic treatment including irradiation within 14 days (42 days for&#xD;
             mitomycin c) prior to start of therapy.&#xD;
&#xD;
          6. Major surgery within 4 weeks of starting therapy within this study, or minor&#xD;
             surgery/subcutaneous venous access device placement within 7 days prior to first dose&#xD;
             of protocol therapy. The patient has elective or planned major surgery to be performed&#xD;
             during the course of the clinical trial.&#xD;
&#xD;
          7. Symptomatic brain metastasis&#xD;
&#xD;
          8. Clinically significant cardiovascular disease&#xD;
&#xD;
               -  NYHA&gt;II°, myocardial infarction within 6 months prior study entry&#xD;
&#xD;
               -  Known clinically significant valvular defect&#xD;
&#xD;
               -  Uncontrolled or poorly-controlled hypertension (&gt;160 mmHg systolic or &gt;100 mmHg&#xD;
                  diastolic for &gt;4 weeks) despite standard medical management&#xD;
&#xD;
               -  Any arterial thromboembolic events, including but not limited to myocardial&#xD;
                  infarction, transient ischemic attack, cerebrovascular accident, or unstable&#xD;
                  angina, within 6 months prior to first dose of protocol therapy&#xD;
&#xD;
               -  History of deep vein thrombosis (DVT), symptomatic pulmonary embolism (PE), or&#xD;
                  any other significant thromboembolism (venous port or catheter thrombosis or&#xD;
                  superficial venous thrombosis are not considered &quot;significant&quot;) during the 3&#xD;
                  months prior to first dose of protocol therapy&#xD;
&#xD;
          9. Active clinically serious infections (&gt; grade 2 NCI-CTC version 4.0)&#xD;
&#xD;
         10. Chronic inflammatory bowel disease&#xD;
&#xD;
         11. History of uncontrolled HIV infection or chronic hepatitis B or C&#xD;
&#xD;
         12. Patients with evidence of bleeding diathesis&#xD;
&#xD;
         13. Grade 3-4 GI bleeding within 3 months prior to first dose of protocol therapy&#xD;
&#xD;
         14. Receiving chronic antiplatelet therapy, including aspirin (once daily aspirin use&#xD;
             (maximum dose 325 mg/day) is permitted), nonsteroidal anti-inflammatory drugs&#xD;
             (including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar&#xD;
             agents&#xD;
&#xD;
         15. History of gastrointestinal perforation or fistulae in past 6 months or risk factors&#xD;
             for perforation&#xD;
&#xD;
         16. Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to first&#xD;
             dose of protocol therapy&#xD;
&#xD;
         17. Past or current history of other malignancies not curatively treated and without&#xD;
             evidence of disease for more than 5 years, except for curatively treated basal cell&#xD;
             carcinoma of the skin and in situ carcinoma of the cervix or bladder, or&#xD;
             low/intermediate risk prostate cancer (Gleason score ≤7) with normal PSA levels&#xD;
&#xD;
         18. Any condition that could jeopardize the safety of the patient and their compliance of&#xD;
             the study&#xD;
&#xD;
         19. Medical, psychological or social conditions that may interfere with the participation&#xD;
             in the study&#xD;
&#xD;
         20. Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a&#xD;
             history of hepatic encephalopathy or ascites.&#xD;
&#xD;
             Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics&#xD;
             or paracentesis&#xD;
&#xD;
         21. On-treatment participation in another clinical study or received investigational drug&#xD;
             therapy in the period 30 days prior to inclusion and during the study&#xD;
&#xD;
         22. Subject pregnant or breast feeding, or planning to become pregnant within 7 months&#xD;
             after the end of treatment&#xD;
&#xD;
         23. Patients in a closed institution according to an authority or court decision (AMG §&#xD;
             40, Abs. 1 No. 4)&#xD;
&#xD;
         24. Any other concurrent antineoplastic treatment including irradiation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah-Eddin Al-Batran, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Kasper-Virchow, Prof. Dr.</last_name>
    <phone>+49201723</phone>
    <phone_ext>3449</phone_ext>
    <email>stefan.kasper@uk-essen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Pauligk, Dr.</last_name>
    <phone>+49697601</phone>
    <phone_ext>3906</phone_ext>
    <email>ramtas@ikf-khnw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Altenburger Land GmbH</name>
      <address>
        <city>Altenburg</city>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>MVZ Gesundheitszentrum St. Marien GmbH</name>
      <address>
        <city>Amberg</city>
        <zip>922241</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludwig Fischer von Weikersthal, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Pink, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susen Burock, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Seestrasse</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Schmittel, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.-Johannes-Hospital</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Hagen, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Graf, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Kasper, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest GmbH</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten O Goetze, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Stein, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Hamburg Barmbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Prasnikar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arndt Vogel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Herne</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Strumberg, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vincentius-Diakonissen-Kliniken gAG</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Kolov, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albrecht Hoffmeister, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Angermeier, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tagestherapiezentrum am ITM Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf D Hofheinz, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans J Tischler, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ullrich Graeven, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München-Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Heinemann, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unversitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kerkhoff, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Siegler, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Dechow, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedCenter Nordsachsen</name>
      <address>
        <city>Schkeuditz</city>
        <zip>04435</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Edelmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leopoldina Krankenhaus</name>
      <address>
        <city>Schweinfurt</city>
        <zip>97422</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Kanzler, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Klinik Dr. Hancken GmbH</name>
      <address>
        <city>Stade</city>
        <zip>21680</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Meiler, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Ettrich, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Wilhelmshaven</name>
      <address>
        <city>Wilhelmshaven</city>
        <zip>26389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tanja Trarbach, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-Onkologische Praxis</name>
      <address>
        <city>Würselen</city>
        <zip>52146</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Maintz, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>ramucirumab</keyword>
  <keyword>tas102</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramucirumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

